Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MS and depression: new study probes how patients read emotions

NCT ID NCT02468765

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at how depression affects the ability to recognize emotions in people with multiple sclerosis (MS). Researchers used EEG, heart rate monitoring, and questionnaires to compare emotion recognition in MS patients with and without depression, as well as healthy controls. The goal was to better understand the link between mood disorders and emotional processing in MS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand how depression impacts emotion recognition in MS, potentially leading to improved mental health support.
What could go wrong
This is a small, observational study with only 38 participants. It does not test a treatment, so it cannot directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

38 people

The number who actually took part.

Started

Apr 2015

Finished

May 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Three groups will participate: Depressive MS patients, non depressive MS patients and a control group

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Man or Woman between 18 and 65 years old * Participant understanding and able to speak French * Participant understanding the Participant Informed Sheet and who has signed the Informed Consent * Participant with Health Insurance MS Patients : * Patient with relapsing remitting multiple sclerosis form * Expanded Disability Status Scale (EDSS) \< 4 * Patient without motor disorders, cerebellar or significant upper limb somatosensory or visual disturbances Control Participants : * Participant without global cognitive deterioration Exclusion Criteria: * Participant taking part of other biomedical studies involving drug tests * Participant with other neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, alcoholism, perception disorders, dysarthria, disorders preventing oral communication and reading, under prescription of psychotropic drugs * Mental or visual incapacity to take part in the study * Participant with antecedents of drug or alcohol abuse * Allergy to the components of the gel used during the EEG * Patients with MRI contraindications : Pacemaker or neurostimulator or Implantable Cardioverter Defibrillator (ICD), Cochlear Implants, ocular or cerebral ferromagnetic foreign body close to the nerve structures, metal prostheses, * Uncooperative or agitated patients, * Claustrophobic patients, * Ventricular peritoneal shunts and neurosurgical valves, * Braces * MS patient without MRI in the last 4 months * Adults under guardianship, under judicial protection, persons deprived of liberty, * Pregnant or breast feeding women, * MS patient with another MS form than Relapsing-Remitting, * MS patient who encountered a relapse in the last 6 weeks, * MS patient treated with corticoids in the last month.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Saint Vincent de Paul (GHICL)

    Lille, Hauts-de-France, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.